• No se han encontrado resultados

CAPÍTULO II: FORMAS DE USO DEL ESPACIO EN EL HOGAR ACTUAL DEL CENTRO URBANO DE SANTA CLARA.

2.2 Resultados del trabajo de campo

The   preceding   chapter   in   this   thesis   demonstrated   that   cortisol   concentrations   were   increased  in  the  lungs  of  patients  with  ARDS.  It  also  showed  that  the  cortisol:  cortisone   ratio   was   increased   in   the   alveolar   space   of   patients   with   ARDS,   suggesting   increased   local  activity  of  11β-­‐HSD  type  1  oxo-­‐reduction  of  cortisone  to  cortisol.  In  this  chapter  we   have  demonstrated  that  the  inflammatory  mediators  TNF-­‐α  and  IL-­‐1β,  which  have  both   previously  been  demonstrated  to  be  key  mediators  in  ARDS,10,  221  cause  an  up-­‐regulation   of  11β-­‐HSD  oxo-­‐reductase  activity  in  primary  human  alveolar  macrophages.  

The  effect  of  the  pro-­‐inflammatory  cytokines  TNF-­‐α  and  IL-­‐1β  on  11β-­‐HSD  activity  has   been  observed  previously  in  other  cell  types.  Cooper  et  al.  showed  in  osteoblasts  that   not   only   did   these   cytokines   increase   the   11β-­‐HSD   type   1   conversion   of   cortisone   to   cortisol,  a  suppression  of  the  deactivation  of  cortisol  to  cortisone  by  11β-­‐HSD  type  2  was   also  observed.64    Similar  responses  to  these  cytokines  have  been  seen  in  many  other  cell   types   including   adipocytes,   hepatocytes,62   smooth   muscle,65   and   amnion   and   skeletal   muscle  fibroblasts.  54,  63    

That  LPS  caused  a  decrease  in  the  11β-­‐HSD  oxo-­‐reductase  activity  is  unexpected  given   the   finding   that   the   other   inflammatory   molecules   caused   an   up-­‐regulation   of   this   activity.  We  are  unable  to  find  any  other  reports  of  a  similar  response  to  LPS  stimulation.   Indeed,  other  investigators  have  demonstrated  that  human  macrophage  11β-­‐HSD  type  1   mRNA  and  activity  are  up-­‐regulated  by  LPS.210  Why  we  should  have  observed  a  different   result  is  not  clear,  especially  as  the  action  of  LPS  on  macrophages  is  to  cause  them  to   produce   TNF-­‐α,   which   we   have   shown   to   up-­‐regulate   rather   than   down-­‐regulate   oxo-­‐ reductase  activity.  An  altered  response  to  LPS  in  these  macrophages  is  a  possibility,  but   further  investigation  is  needed  before  such  a  finding  should  be  accepted.    

HMGB-­‐1   is   released   from   activated   macrophages   in   response   to   pro   inflammatory   mediators  such  as  TNF-­‐α,  IL-­‐1β  or  LPS,  and  also  causes  the  release  of  TNF-­‐α  and  IL-­‐1β   from  macrophages.223  It  is  thought  to  be  a  late  mediator  of  sepsis  and  inflammation.224   We  were  not  able  to  show  any  alteration  in  11β-­‐HSD  activity  induced  by  stimulation  of   the  alveolar  macrophages  with  this  mediator.  The  absence  of  an  increase  in  activity  in   response   to   HMGB-­‐1,   together   with   the   declining   increase   in   activity   induced   by   BALF   from   day   4   of   ARDS   suggest   therefore   that   the   induction   of   11β-­‐HSD   oxo-­‐reductase  

activity  may  be  a  phenomenon  situated  early,  rather  than  late,  in  the  signalling  pathway   of  ARDS.  

We  were  also  unable  to  demonstrate  a  consistent  effect  of  salbutamol  on  otherwise  un-­‐ stimulated   alveolar   macrophages.   However,   when   co-­‐stimulated   with   the   pro-­‐ inflammatory   cytokine   TNF-­‐α,   salbutamol   caused   a   down-­‐regulation   of   the   induced   increase   in   oxo-­‐reductase   activity,   through   the   activation   of   the  β-­‐adrenoceptor.   Why   salbutamol   should   only   cause   such   a   response   in   co-­‐stimulated   cells   is   not   clear:   It   is   possible  that  the  salbutamol  induced  changes  are  only  detectable  with  greater  activity,   but  also  that  the  mechanism  by  which  salbutamol  acts  is  through  a  pathway  activated   only   by   the   cytokines   in   question.   In   contrast   to   our   findings   Friedberg   et   al.   demonstrated  that  although  the  11β-­‐HSD  type  1  activity  in  adipocytes  was  increased  by   pro-­‐inflammatory  cytokines,  it  was  also  increased  by  salbutamol.56  That  we  showed  an   opposite  effect  is  likely  to  represent  phenotypic  differences  between  the  cells  studied.  A   tissue   specific   response   of   11β-­‐HSD   to   similar   stimulations   has   been   demonstrated   by   Tomlinson  et  al.  between  adipocytes  and  hepatocytes.62  

The  experiments  incubating  alveolar  macrophages  with  BALF  from  patients  with  ARDS   were   designed   to   approximate   the   conditions   that   alveolar   macrophages   might   be   exposed   to   in-­‐vivo,   and   in   so   doing   examine   the   mechanisms   by   which   the   observed   enzyme  activity  develops.  These  experiments  have  many  factors  that  require  a  caution   to  be  used  in  their  interpretation.  The  culture  conditions  consist  of  BALF  mixed  in  a  1:1   ratio  with  the  normal  culture  medium,  leading  to  a  less  physiological  environment  for   these  cells.  Despite  these  caveats  the  increase  in  the  oxo-­‐reductase  activity  of  alveolar   macrophages   caused   by   incubation   with   ARDS   BALF   is   nevertheless   convincing.   These  

results  are  in  keeping  with  our  findings  that  pro-­‐inflammatory  cytokines  up-­‐regulate  the   11β-­‐HSD  oxo-­‐reductase  activity.  

Macrophage  11β-­‐HSD  type  1  activity  is  important  in  the  host  response  to  injury  and  the   resolution  of  inflammation.  Macrophages  are  responsible  for  the  safe  disposal  of  spent   inflammatory  cells  that,  and  11β-­‐HSD  activity  promotes  this  process  in  animal  models  by   increasing   available   intracellular   cortisol.75   Failure   of   uptake   of   apoptotic   cells   leads   these   dying   cells   to   undergo   secondary   necrosis   and   release   further   pro-­‐inflammatory   mediators,229   leading   to   further   tissue   damage   and   the   perpetuation   of   the   inflammatory   process.230   Any   failure   of   these   mechanisms,   and   an   insufficient   up-­‐ regulation  of  11β-­‐HSD  oxo-­‐reductase  activity  in  alveolar  macrophages  would  therefore   be  of  functional  importance  in  the  resolution  of  inflammation  in  ARDS.    If  LPS  were  to  be   present   in   sufficient   concentrations   to   suppress   11β-­‐HSD   oxo-­‐reductase   activity,   this   could  lead  to  prolonged  disease  in  ARDS.  

One  further  consideration  of  the  interpretation  of  these  experiments  is  that  in  this  only   one  cell  type  has  been  studied.  Alveolar  macrophages  are  essential  effector  cells  in  the   resolution  of  ARDS,  and  11β-­‐HSD  activity  within  these  cells  will  influence  their  function.   However,   the   total   lung   cortisol:   cortisone   ratio   cannot   be   solely   attributed   to   these   cells.  The  response  of  other  cell  types  within  the  lung  to  inflammatory  stimuli  should  be   further   investigated.   The   histopathology   study   performed   by   Suzuki   et   al   located   an   increase  in  11β-­‐HSD  type  2  in  the  alveolar  cell  wall,  as  well  as  in  CD68  positive  cells  in   the   alveolar   lumen.69   Our   results   show   that   at   least   in   these   CD68   positive   resident   alveolar   macrophages,   inflammatory   stimuli   do   not   increase   net   local   cortisol   production.  We  cannot  as  yet  inform  on  the  activity  present  in  other  lung  cells.  

In  conclusion,  these  experiments  have  shown  that  the  11β-­‐HSD  activity  oxo-­‐reductase   activity   of   primary   human   alveolar   macrophages   is   increased   by   pro-­‐inflammatory   cytokines,   and   in   a   BALF   model   of   ARDS.   LPS   However   decreases   this   activity.   These   findings  provide  a  cellular  mechanism  for  the  increased  cortisol:  cortisone  ratio  present   in   the   lungs   of   patients   with   ARDS   that   was   identified   in   the   previous   chapter.   This   increase   in   11β-­‐HSD   oxo-­‐reduction   of   cortisone   to   cortisol   amplifies   the   anti-­‐ inflammatory  signal  by  increasing  available  cortisol.  

Documento similar